Hims & Hers Health (HIMS) Projected to Post Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is projected to release its earnings data after the market closes on Monday, February 24th. Analysts expect Hims & Hers Health to post earnings of $0.09 per share and revenue of $470.50 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Hims & Hers Health Price Performance

HIMS opened at $49.10 on Friday. Hims & Hers Health has a fifty-two week low of $9.25 and a fifty-two week high of $72.98. The firm has a market capitalization of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35. The company’s 50 day moving average price is $35.05 and its two-hundred day moving average price is $25.76.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 101,993 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $29.62, for a total value of $3,021,032.66. Following the transaction, the chief financial officer now directly owns 109,392 shares of the company’s stock, valued at approximately $3,240,191.04. This trade represents a 48.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael Chi sold 7,259 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at $4,659,976.07. This trade represents a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,184,611 shares of company stock valued at $40,338,442 over the last ninety days. 17.71% of the stock is owned by corporate insiders.

Analyst Ratings Changes

HIMS has been the topic of a number of recent analyst reports. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Piper Sandler boosted their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Monday, January 6th. Finally, Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.53.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.